Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
Peter Brodersen is a Professor at the Department of Biology, University of Copenhagen , specializing in Bioinformatics and RNA Biology . His research focuses on RNA modification (m6A), YTHDF proteins, and small RNA pathways in plants. Recent research trends from his group include: (1) molecular mechanisms of ARGONAUTE-small RNA interactions, (2) m6A-YTHDF regulatory systems in plant development, and (3) RNAi-independent roles of DICER-LIKE proteins in antiviral defense. Collaborations span Denmark and international institutions. Publications highlight cross-disciplinary work bridging computational biology and experimental plant genetics. Key subfields include RNA structure, epigenetic regulation, and antiviral immunity.
Florian Huber is a Research Associate at Paracelsus Medical University's Institute of Pharmacology and Toxicology, investigating molecular mechanisms of genetic hearing disorders. His work focuses on ubiquitin-proteasome regulation of pendrin (SLC26A4) variants associated with Pendred syndrome. Recent studies demonstrate how proteasome inhibitors rescue function of pathogenic pendrin mutants, offering therapeutic pathways for hearing restoration. Huber develops experimental and computational approaches to map degradation pathways of membrane transport proteins. He supervises medical doctoral candidates and teaches pharmacology in graduate programs.
Thibault Mayor is a Professor in the Department of Biochemistry and Molecular Biology and the Michael Smith Laboratories at the University of British Columbia (Vancouver). His research focuses on understanding how cells manage misfolded proteins, with implications for neurodegenerative diseases like Parkinson's and Alzheimer's. He holds academic affiliations with the Centre for High-Throughput Biology (CHiBi) and has been recognized with awards including the UBC Killam Teaching Award (2020). Education: BSc, University of Geneva, Switzerland (1997) PhD, University of Geneva & Max Planck Institute of Biochemistry, Germany (2001) Postdoctoral Fellow, California Institute of Technology (2002) Research Interests: Mayor's lab investigates protein homeostasis, ubiquitin-proteasome system dynamics, and the molecular mechanisms underlying protein aggregation in aging and disease. Projects include proteomic approaches to identify aggregation-prone proteins and develop microbial cell factories for protein production. Grants & Awards: CIHR Project Grant ($730K, 2018) Michael Smith Foundation Career Award (2012) UBC Killam Teaching Award (2020) Labs & Collaborations: The Mayor Lab is part of the Michael Smith Laboratories and collaborates with computational biologists like Jörg Gsponer. They maintain active partnerships in proteomics and systems biology, contributing to initiatives like the BC Proteomics Network.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
University of California, Los AngelesUnited States
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Heidelberg Institute for Theoretical StudiesGermany
Overview Sebastian Schuck is a Professor of Biochemistry and Molecular Cell Biology at Heidelberg University's Biochemistry Center (BZH). His research focuses on organelle homeostasis, particularly the endoplasmic reticulum (ER), with emphasis on ER membrane biogenesis, ER-phagy, and SHRED pathways. He leads an international team investigating how cells adapt ER structure and function under stress or disease conditions. Education & Career Since 2021: Professor at Heidelberg University BZH 2013–2021: Independent Group Leader at Heidelberg University's Center for Molecular Biology 2006–2013: Postdoc with Peter Walter at UCSF 2001–2006: PhD and Postdoc with Kai Simons at Dresden's Max Planck Institute 1995–2000: Biochemistry studies at Universities of Hannover and Tübingen Research Interests Dr. Schuck's lab explores molecular mechanisms underlying ER homeostasis, including: 1. ER expansion during stress via lipid synthesis 2. Microautophagy-mediated ER degradation via ESCRT machinery 3. SHRED pathway regulation of proteasomal degradation of misfolded proteins 4. Links between ER stress and neurodegenerative diseases/cancer Awards & Honors No specific awards listed, but recognized for pioneering contributions to understanding microautophagy and ER quality control mechanisms. Advising & Collaborations Advised over 20 PhD/Master's students and postdocs Collaborations with Carlos Bas-Orth (MPI Biochemistry), Liam Holt (NY), and others Labs & Teams Current lab includes 10+ members focusing on: - Human ER morphogenesis - Microautophagy dynamics - SHRED pathway mechanisms
Christian Friedrich Wilhelm Becker is a full Professor at the University of Vienna, holding a position within the Faculty of Chemistry and the Department of Biological Chemistry. His research profile shows extensive activity in protein chemistry and biochemistry, with particular focus on post-translational modifications and their implications in disease mechanisms. His work bridges chemical biology, biochemistry, and biomedical applications, contributing significantly to the academic and research landscape at one of Europe's oldest and most prestigious universities. Faculty of Chemistry, University of Vienna Department of Biological Chemistry Active research leader with numerous ongoing projects Significant publication record spanning multiple disciplines Professor Becker's research primarily focuses on protein chemistry, particularly post-translational modifications and their role in protein function and dysfunction. His work spans multiple interconnected areas including ubiquitination, protein aggregation, prion protein behavior, and biomimetic approaches to protein analysis. His research has significant implications for understanding neurodegenerative diseases and developing novel therapeutic approaches. The fingerprint analysis of his work shows strong connections to biochemistry, molecular biology, and chemistry, with particular emphasis on cysteine chemistry, glycosylation, and amino acid modifications. Analysis of Professor Becker's recent publications (2021-2025) reveals a consistent research trajectory focused on protein modification techniques and their biological implications. His work shows increasing sophistication in chemical biology approaches to study protein function, with particular emphasis on ubiquitination pathways and protein aggregation mechanisms. The integration of chemical synthesis methods with biological analysis represents a hallmark of his research approach. His publications span high-impact journals in biochemistry, chemical biology, and peptide science, demonstrating the interdisciplinary nature of his contributions. Professor Becker has received notable recognition for his research contributions, most prominently the Cathay Award in 2020. This award acknowledges his significant contributions to the field of protein chemistry and chemical biology. His work appears to have practical applications in therapeutic development, particularly in the areas of targeted protein degradation and immunotherapy, which likely contributed to this recognition. Cathay Award (2020) Professor Becker leads multiple significant research projects, including 'Targeted protein degradation - from small molecules to complex organelles' (2020-2024), 'Taktira: Development of an improved, low-side-effect and sustainable immunotherapy' (2019-2023), and 'Structure Zoom: Zooming in on protein functional sites with atomic resolution' (2018-2021). These projects demonstrate substantial grant funding and collaborative research efforts across multiple institutions. His active participation in 290 recorded activities through 2025 indicates a highly engaged research program with numerous collaborators and trainees. Targeted protein degradation project (2020-2024) Taktira immunotherapy project (2019-2023) Structure Zoom project (2018-2021) Professor Becker's research environment includes a robust team of collaborators and junior researchers, as evidenced by the numerous co-authored publications and activities. His work intersects with multiple research groups studying protein function, modification, and therapeutic applications. The international collaboration network shown in his profile indicates significant engagement with researchers across multiple countries, creating a dynamic research ecosystem focused on advancing protein science and its biomedical applications.
Lin He is the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research and Professor of Cell Biology and Physiology at the University of California, Berkeley. His laboratory focuses on understanding the biological functions of non-coding RNAs in development and disease, with particular emphasis on microRNAs (miRNAs) in cancer, stem cell biology, and developmental processes. He developed the CRISPR-EZ method for highly efficient mouse genome editing, significantly advancing genetic research. Research interests include miRNAs' roles in tumor progression, metastasis, and pluripotency regulation in stem cells. His work bridges mouse genetics, genomics, and molecular biology to uncover mechanisms governing non-coding RNA functions. Current projects address miRNAs in oncogenesis, stem cell fate determination, and the interplay between non-coding RNAs and retrotransposons in development. Key contributions include identifying miRNA networks in cancer pathways, demonstrating miRNA requirements for ciliogenesis and lung development, and advancing CRISPR-based genome editing techniques. His interdisciplinary approach integrates genetic, genomic, and cellular tools to explore fundamental questions in biology and medicine. Lab website: helabucb.org CRISPR-EZ technology enables 100% genome editing efficiency in mouse zygotes Pioneering studies on miRNA regulation of PTEN, p53, and oncogene pathways
Dr. Jacques Archambault is a Professor in the Department of Microbiology and Immunology at McGill University , and an associate member of the Division of Experimental Medicine since 2016. His research focuses on the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), with an emphasis on their replication mechanisms as episomes in host cells. The Archambault laboratory employs functional genomics, proteomics, and chemical biology approaches to identify cellular pathways exploited by these viruses and develop high-throughput assays for screening small molecule inhibitors of viral replication. Analysis of his recent publications reveals a strong focus on HPV and HPyV replication machinery, including studies on the E1 helicase, UAF1-USP1 interactions, and structural characterization of viral proteins involved in DNA replication. His work bridges virology, oncology, and drug discovery, particularly targeting oncogenic HPV types implicated in anogenital and oropharyngeal cancers, as well as HPyVs like BKPyV and JCPyV that cause pathologies in immunosuppressed patients. Current efforts in the lab aim to elucidate the molecular mechanisms by which HPVs and HPyVs replicate their genomes and to develop antiviral therapies targeting these processes. Techniques such as fluorescence anisotropy, NMR spectroscopy, and crystallography are frequently employed to study protein-DNA and protein-protein interactions critical to viral replication.
Gustavo M. Silva is the Jack H. Neely Associate Professor of Biology at Duke University's Trinity College of Arts & Sciences, a position he has held since 2025. Previously, he served as Associate Professor of Biology (2024-present) and Assistant Professor of Cell Biology (2022-present) at Duke. His research is conducted through the Silva Lab (sites.duke.edu/silvalab), which focuses on molecular mechanisms of cellular stress response. Education: Ph.D. from University of Sao Paulo (Brazil), 2010 B.Sc. from University of Sao Paulo (Brazil), 2004 Dr. Silva's research centers on understanding how gene expression is regulated at transcriptional and translational levels during cellular stress. His lab specifically investigates how the ubiquitin system controls protein synthesis and degradation dynamics under stress conditions, which are critical for cellular physiology. His work has significant implications for understanding disease mechanisms where protein homeostasis is disrupted. The research combines biochemical, genetic, and proteomic approaches to dissect these complex regulatory networks. His publication record demonstrates a clear evolution from fundamental studies on redox regulation and proteasome function to more complex investigations of ubiquitin signaling in translation control and stress response. Recent work increasingly focuses on K63-linked ubiquitination's role in ribosome function and translation regulation, with growing emphasis on the clinical implications of these mechanisms in disease contexts including cancer. Scientific Awards & Recognition: Paul T. Englund Emerging Scholar Award (Johns Hopkins School of Medicine, 2024) Dean's Award for Excellence in Mentoring (Duke Graduate School, 2023) Science Diversity Leadership Award (Chan Zuckerberg Initiative, 2022) Best Professor Award (Vanderbilt Basic Sciences Juneteenth Committee, 2022) 100 inspiring Black scientists in America (CellPress, 2020) Dr. Silva actively mentors students at multiple levels, as evidenced by his Dean's Award for Excellence in Mentoring. His research is supported by substantial funding including NIH grants such as the Tri-Institutional Molecular Mycology and Pathogenesis Training Program (2024-2029) and 'Stalling cancer at the ribosome' from the V Foundation for Cancer Research (2025-2028). He also serves as Principal Investigator on multiple R01 grants focused on ubiquitin's role in translation control and stress response. The Silva Lab maintains strong collaborative relationships with institutions including the Chan Zuckerberg Initiative and ETH Zurich, and participates in several interdisciplinary training programs at Duke that support underrepresented students in biomedical sciences.
Dr. Jason Yi is an Assistant Professor of Neuroscience at Washington University School of Medicine (WashU Medicine). His research focuses on understanding the molecular pathways that shape nervous system development and function, with particular emphasis on autism spectrum disorders (ASD). He leads the Yi Lab, which investigates the role of the ubiquitin ligase UBE3A in the brain and its implications for neurodevelopmental disorders. Dr. Yi received his BS in Biochemistry and Molecular Biology from Dickinson College in 2001 and his PhD in Pharmacology from Duke University in 2009. His laboratory is broadly interested in the molecular pathways that shape nervous system development and function, with the ultimate goal of understanding how dysfunction in these pathways contributes to disease. The current focus is on autism spectrum disorders (ASD), using genetic information from human patients to guide in vitro and in vivo experiments employing biochemical, genetic manipulation, cell biological, and microscopy techniques. Dr. Yi's research has significant clinical implications, particularly in understanding how UBE3A dysfunction relates to both Angelman syndrome (caused by lack of UBE3A activity) and autism (caused by excessive UBE3A activity). His lab discovered that a single phosphorylation event in UBE3A turns off its ubiquitin ligase activity, and that mutations in this site are linked to autism. This work bridges disease genetics with a mechanistic understanding of ASD neurobiology and aims to define developmental timepoints for ASD onset. Dr. Yi's research has been recognized with numerous prestigious awards: Ruth K. Broad Biomedical Research Foundation Predoctoral Fellowship (2006) F32 Kirschstein National Research Service Award (2011) Christina Castellana Postdoctoral Fellowship (2011-2014) The University of North Carolina Postdoctoral Award for Research Excellence (2015) Bridge to Independence Award, The Simons Foundation (2017) NARSAD Young Investigator Award, Brain and Behavior Research Foundation (2018) Whitehall Foundation Research Grant (2018) Alfred P. Sloan Foundation Research Fellowship (2019) Dr. Yi's research program is supported by significant grant funding from organizations including The Simons Foundation, Brain and Behavior Research Foundation, and the Whitehall Foundation. His work bridges basic molecular neuroscience with clinical implications for neurodevelopmental disorders, particularly autism spectrum disorders. Through his research, Dr. Yi is contributing to a deeper understanding of the molecular mechanisms underlying ASD, which may ultimately lead to new therapeutic approaches and interventions. The Yi Lab maintains a collaborative research environment focused on cutting-edge neuroscience techniques. The lab combines molecular, cellular, and genetic approaches to study UBE3A function and its role in neurodevelopment. Their work utilizes patient-derived genetic information to guide experimental approaches, ensuring clinical relevance to autism spectrum disorders. Dr. Yi is also actively involved in mentoring graduate students and postdoctoral fellows, contributing to the training of the next generation of neuroscientists.
Dr. Xin Li is a Professor at the University of British Columbia (UBC), affiliated with the Michael Smith Laboratories and the Department of Botany. She holds a Tier 1 Canada Research Chair in Plant Immunity and leads research on plant innate immunity mechanisms, focusing on molecular pathways in Arabidopsis thaliana. Her work explores how plants defend against pathogens through gene regulation, protein interactions, and signal transduction. Education: BSc in Genetics from Fudan University (1989), PhD in Plant Pathology from Oklahoma State University (1995), postdoctoral training at Duke University (1996-1999). Prior to UBC, she was a Scientist at Maxygen, Inc. (1999-2001). Research spans biochemistry, genomics, and proteomics, with a focus on regulatory components of plant disease resistance. Key areas include NLR immune receptors, salicylic acid signaling, and translational strategies for sustainable agriculture. Lab members include PhD students (e.g., Paul Kapos, Kevin Ao), MSc students (e.g., Nanbing Zhang), and postdocs (e.g., Tongjun Sun). The Li Lab collaborates internationally, notably through the PRoTECT training program funded by NSERC and DFG. Notable awards include the Tier 1 CRC nomination (2022) and grants supporting the PRoTECT initiative. Her research has led to over 70 peer-reviewed publications, advancing understanding of plant immunity and its applications in crop protection.
Dr. Richard Y. Zhao is a tenured Professor in the Department of Pathology and Microbiology-Immunology at the University of Maryland School of Medicine. His research combines molecular biology, fission yeast genetics, mammalian biology, and virology to study virus-host interactions, particularly for HIV and Zika virus. He previously held academic positions at Northwestern University and Columbia University and has contributed to over 120 peer-reviewed articles. B.S., China Oceanography University (1981) M.S., Oregon State University (1995) Ph.D., Oregon State University (1991) Postdoctoral Training, Columbia University (1991-1992) Dr. Zhao's research focuses on: Virus-host interactions and pathogenicity High-throughput drug screening for antivirals Role of viral proteins in neuroinflammation and cancer Translational genomics in precision medicine His recent publications highlight SARS-CoV-2 ORF3a, Zika envelope proteins, and HIV protease inhibitors, emphasizing host-pathogen mechanisms across species. He has served on NIH panels and editorial boards for journals like Cell Research and Retrovirology . Scientific awards include: Fellow, American Academy of Microbiology (2019) Bernard L Mirkin Endowed Chair (2001-2004) Honorary Director, Shandong Gallo Institute (2009) Distinguished Service from SCBA (2015) Outstanding Service from CBA-USA (2016) Dr. Zhao also contributes to clinical diagnostics and personalized medicine through molecular testing and pharmacogenetics programs.
Ramanujan Hegde serves as a Professor and Group Leader at the MRC Laboratory of Molecular Biology (LMB), University of Cambridge, where he directs research on membrane protein biosynthesis and cellular quality control mechanisms. His work examines how membrane proteins are accurately targeted to organelles, inserted into lipid bilayers, folded, and assembled into functional complexes, with emphasis on the cellular pathways that eliminate defective proteins to prevent disease. Professor Hegde's research program focuses on fundamental questions in cell biology: How do cells ensure precise membrane protein localization? What molecular machinery governs protein insertion and folding? How do quality control systems detect and degrade misfolded proteins? His investigations reveal that biosynthetic failures are common, triggering degradation pathways linked to diseases like neurodegeneration. Key research areas include: Intramembrane chaperone mechanisms for multipass membrane proteins Orphan subunit recognition during complex assembly Ribosome-associated mRNA degradation in autoregulation Proteasome assembly quality control ER membrane protein complex functions Molecular basis of protein aggregation diseases His 2017-2023 publications in Cell, Nature, and Science demonstrate consistent innovation in protein quality control, with landmark discoveries including UBE2O's role in orphan subunit degradation, the EMC as a transmembrane domain insertase, and TTC5-mediated tubulin autoregulation. These works bridge basic cell biology with disease mechanisms through rigorous biochemical and structural approaches. Professor Hegde mentors a research team of 11 scientists: Christine Desroches Altamirano Zhong Yan Gan Dino Janssen Ryan Judy Jennifer Miao Elizabeth Miller Tim Stevens Julia Toplak Huping Wang Haoxi Wu Eszter Zavodszky His laboratory operates within the MRC LMB's world-class infrastructure, utilizing advanced techniques in biochemistry, structural biology, and cell imaging. Supported by Medical Research Council funding, the group maintains strong collaborations across Cambridge and internationally to dissect protein biogenesis pathways with implications for therapeutic development in protein-misfolding disorders.
